Efficacy of Lenvatinib Plus Pembrolizumab and Sunitinib in Advanced RCC
Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Viktor Grünwald, MD, PhD, of Hannover Medical School, reviews the efficacy findings of lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) and sunitinib (Sutent) for the treatment of patients with advanced renal cell carcinoma (RCC) presented during the 2021 American Society of Clinical Oncology Annual Meeting.
In the CLEAR study, investigators noticed an impact in efficacy that was irrespective of the adverse event profile. In terms of progression-free survival, the results were similar in patients who were considered to have favorable risk and those who had at least 1 risk parameter. Grunwald also states that the highest complete responders to the combination were those with favorable risk.
The findings related to the difference between patients with favorable-risk and high-risk advanced RCC are descriptive, notes Grunwald and require further research.
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
LITESPARK-005 Trial of Belzutifan Shows Survival Benefits in Advanced Clear Cell RCC
September 13th 2024A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.
Read More
